115 related articles for article (PubMed ID: 23847381)
1. GM-CSF/Ipilimumab combination extends melanoma survival.
Cancer Discov; 2013 Jul; 3(7):OF6. PubMed ID: 23847381
[TBL] [Abstract][Full Text] [Related]
2. Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma.
Luke JJ; Donahue H; Nishino M; Giobbie-Hurder A; Davis M; Bailey N; Ott PA; Hodi FS
Cancer Immunol Res; 2015 Sep; 3(9):986-91. PubMed ID: 25943535
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Weber JS; D'Angelo SP; Minor D; Hodi FS; Gutzmer R; Neyns B; Hoeller C; Khushalani NI; Miller WH; Lao CD; Linette GP; Thomas L; Lorigan P; Grossmann KF; Hassel JC; Maio M; Sznol M; Ascierto PA; Mohr P; Chmielowski B; Bryce A; Svane IM; Grob JJ; Krackhardt AM; Horak C; Lambert A; Yang AS; Larkin J
Lancet Oncol; 2015 Apr; 16(4):375-84. PubMed ID: 25795410
[TBL] [Abstract][Full Text] [Related]
4. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies.
Cham J; Zhang L; Kwek S; Paciorek A; He T; Fong G; Oh DY; Fong L
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376721
[TBL] [Abstract][Full Text] [Related]
5. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.
Prieto PA; Yang JC; Sherry RM; Hughes MS; Kammula US; White DE; Levy CL; Rosenberg SA; Phan GQ
Clin Cancer Res; 2012 Apr; 18(7):2039-47. PubMed ID: 22271879
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.
Thompson JA; Hamid O; Minor D; Amin A; Ron IG; Ridolfi R; Assi H; Berman D; Siegel J; Weber JS
J Immunother; 2012 Jan; 35(1):73-7. PubMed ID: 22130164
[TBL] [Abstract][Full Text] [Related]
7. The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety.
Wu Y; Shi H; Jiang M; Qiu M; Jia K; Cao T; Shang Y; Shi L; Jiang K; Wu H
Int J Cancer; 2017 Dec; 141(12):2562-2570. PubMed ID: 28833119
[TBL] [Abstract][Full Text] [Related]
8. The use of granulocyte-macrophage colony-stimulating factor in melanoma treatment.
Hodi FS
Clin Adv Hematol Oncol; 2015 Feb; 13(2):84-6. PubMed ID: 25774475
[No Abstract] [Full Text] [Related]
9. Update on the role of ipilimumab in melanoma and first data on new combination therapies.
Maio M; Di Giacomo AM; Robert C; Eggermont AM
Curr Opin Oncol; 2013 Mar; 25(2):166-72. PubMed ID: 23299197
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.
Simeone E; Ascierto PA
J Immunotoxicol; 2012; 9(3):241-7. PubMed ID: 22524673
[TBL] [Abstract][Full Text] [Related]
11. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer.
Wada S; Jackson CM; Yoshimura K; Yen HR; Getnet D; Harris TJ; Goldberg MV; Bruno TC; Grosso JF; Durham N; Netto GJ; Pardoll DM; Drake CG
J Transl Med; 2013 Apr; 11():89. PubMed ID: 23557194
[TBL] [Abstract][Full Text] [Related]
12. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
O'Day SJ; Boasberg PD; Piro L; Kristedja TS; Wang HJ; Martin M; Deck R; Ames P; Shinn K; Kim H; Fournier P; Gammon G
Clin Cancer Res; 2002 Sep; 8(9):2775-81. PubMed ID: 12231516
[TBL] [Abstract][Full Text] [Related]
13. Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.
Helgadottir H; Kis L; Ljungman P; Larkin J; Kefford R; Ascierto PA; Hansson J; Masucci G
Ann Oncol; 2017 Jul; 28(7):1672-1673. PubMed ID: 28407116
[No Abstract] [Full Text] [Related]
14. The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime?
Postow MA; Callahan MK; Wolchok JD
Clin Cancer Res; 2012 Apr; 18(7):1821-3. PubMed ID: 22338019
[TBL] [Abstract][Full Text] [Related]
15. [Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma].
Robert C; Mateus C
Med Sci (Paris); 2011 Oct; 27(10):850-8. PubMed ID: 22027422
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
[TBL] [Abstract][Full Text] [Related]
17. Clinical use of subcutaneous G-CSF or GM-CSF in malignancy.
Disis ML
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 2):5-9. PubMed ID: 15934493
[No Abstract] [Full Text] [Related]
18. Combination boosts survival for metastatic melanoma.
Tanday S
Lancet Oncol; 2014 Dec; 15(13):e592. PubMed ID: 25499292
[No Abstract] [Full Text] [Related]
19. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
Weber J
Oncologist; 2007 Jul; 12(7):864-72. PubMed ID: 17673617
[TBL] [Abstract][Full Text] [Related]
20. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]